Servier in the news

Servier paid $70M upfront to acquire an early-stage RAS- and RAF-targeted cancer drug from Black Diamond Therapeutics.

Mécénat Servier supports two solidarity projects in Latin America, partnering with TECHO to build emergency housing and with AESC to restore a flood-damaged hospital in Brazil.

Deniz Razon is moving from her role as Chief Business Officer at Servier Pharmaceuticals to a new regional position at Servier in Paris, focusing on global strategic initiatives for oncology and neurology.

Servier selected Veeva OpenData to standardize customer reference data globally, reflecting a growing industry need for high-quality data to scale AI and advanced analytics.

Servier is attending EANS 2026 to present its oncology research and targeted therapies for various cancers.

Servier collaborates with Veeva to standardize global customer data, enhance AI applications, and improve sales and medical team efficiency through integrated data solutions.

Servier finalized its acquisition of Day One Biopharmaceuticals for $2.5 billion, delisting the company from Nasdaq.

Servier is adopting Veeva OpenData globally to standardize customer reference data across more than 80 countries, aiming to create a unified foundation for large-scale AI deployment and improve decision-making.

Servier is adopting Veeva OpenData globally across 80+ countries to standardize customer reference data and establish an AI-ready data foundation for scaling AI initiatives.

Servier is standardizing customer reference data globally using Veeva OpenData to create an AI-ready data foundation and improve commercial execution.

Servier is standardizing customer reference data globally using Veeva OpenData to build an AI-ready foundation.

Servier is implementing Veeva OpenData to standardize customer data and improve AI-driven operations across more than 80 countries.

Servier is globally adopting Veeva OpenData to standardize customer reference data in over 80 countries, building an AI-ready foundation for large-scale AI deployment.

Servier is globally standardizing customer reference data with Veeva OpenData and Link Key People to enhance commercial and medical team insights and actions.

Servier is globally implementing Veeva OpenData to standardize customer data, providing interconnected insights to its teams to accelerate decision-making and AI development.

Servier is actively involved in cardiovascular health through awareness campaigns, supporting early detection, and developing Single Pill Combinations to improve patient adherence to treatments.

Servier Pharmaceuticals emphasizes partnerships to grow its oncology pipeline and expand its rare neurology franchise, as highlighted by its executives at LSX Congress USA.

Servier highlights the importance of early detection and management of cardiovascular diseases, particularly hypertension, and its commitment to developing innovative solutions and supporting global health campaigns.

Servier's Oncology Medical Director discussed the complexities of brain tumor drug development at the American Brain Tumor Association 2026 National Conference.